Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.
BioArctic is a Swedish research intensive biopharma company aimed at developing new treatments that address the causes of diseases that affect the Central Nervous System. These types of treatments are commonly referred to as “disease modifiers”. They affect the underlying disease pathology and can hopefully stop or significantly delay disease progression. This is a large paradigm shift from today’s symptom-oriented therapies.
Centre for Digital Life Norway (DLN) is a national center for biotechnology training, research and innovation.DNL is a response to the strategic initiative “Digital Life – convergence for innovation” funded by the Norwegian Research Council (NRC). DLN is a virtual center, currently involving twelve major research projects, and managed by a joint leadership network from NTNU, UiB and UiO.
InDex Pharmaceuticals lead drug candidate is cobitolimod – a new type of drug that can help patients back to a normal life. InDex has also developed a platform of patent protected substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
NBS-C BioScience is a Contract Research Organisation founded 2009 as a spin off by scientists of the Novartis Institutes of BioMedical Research in Vienna, Austria. The company specializes on contract research for antibody and biosimilar development, protein biochemistry with molecular interaction analysis based on Surface Plasmon Resonance (SPR; Biacore™) technology and develops and commercializes research reagents and kit components for allergy research and diagnostics.
NCK provides cutting edge process development and API manufacturing (e.g. process development, analytical development, reference samples, supply of API for toxicology and human studies, API release, ICH stability studies as well as relevant progress reports and GMP documentation) for biotech and pharma companies who want to take NCEs from discovery to commercialization.